10th Anniversary Drug Discovery 2016

Posters

Mr Chris Morris
STFC
2West-Life: A Virtual Research Environment for Structural Biology
Dr Mymoona Akhter
Faculty of Pharmacy, Jamia Hamdard
3Computational design and validation of some novel, non pteridine analogs as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitorsors
Dr M. Mumtaz Alam
Faculty of Pharmacy, Jamia Hamdard
4Novel pyrazole–pyrazoline hybrids as antimalarial agents: their synthesis and 3D-QSAR studies
Dr Laura Aitken
University of St. Andrews
5The Identification and Characterisation of Small Molecule Human ABAD Inhibitors as Therapeutics in Alzheimer’s Disease
Mr Kristian Bruce
GSK
6VST
Mrs Hayley Saunders
MRC Technology
7Identification and characterisation of novel positive allosteric modulators of the Dopamine D1 Receptor
Dr Laurence Arnold
MRC Technology
8Development of disease modifying anti-osteoarthritis compounds targeting Matriptase
Ms Sururat Adigun
MRC Technology
9Screening ubiquitinated MALT1 to identify novel inhibitors
Dr Sandor Snoeijers
Pepscope BV
11Kinase Profiling using Peptide Arrays and Mass Spec as a Tool to Predict the Effect of Kinase Inhibitors on Patients
Dr Sandor Snoeijers
Pepscope BV
12Kinase Profiling Using Peptide Arrays and Phosphoproteomics
Dr Sandor Snoeijers
Pepscope BV
13Kinase Profiling Using Peptide Arrays and Phosphoproteomics
Dr Sandor Snoeijers
Pepscope BV
14Kinase Profiling Using Peptide Arrays and Phosphoproteomics
Dr Sandor Snoeijers
Pepscope BV
15Kinase Profiling Using Peptide Arrays and Phosphoproteomics
Mr David McCoull
MRC Technology
16Screening for Inhibitors of CSF-1R – A Novel Target in the Treatment of Alzheimer’s Disease.
Vendela Parrow
Dep of Medical Sciences
17SciLifeLab drug discovery
Miss Apeksha Shrivastava
Jamia Hamdard
21Pharmacophore Modeling & Docking Studies of DPP-IV enzyme Inhibitors
Mrs Israa Al-ibadi
University of salford
22Selective Recruitment of Glucocorticoid Receptor By Non-Steroid Ligands: Molecular Study of Novel Anti-Cancer Therapies
Mrs Helen Plant
AstraZeneca Pharmaceuticals
23Evaluation of venoms as a source of novel ligands for drug discovery
Mr Badri Ampolu
Sygnature Discovery
24Drug Discovery Approaches for Epigenetic Targets
Ms Lauren Eades
ApconiX Ltd
26Delivering CiPA to the Client
Mr Kevin Jones
Corning Life Sciences
27In Vitro Hepatotoxicity Profiling Using Corning® Epic® Label-Free Technology with Primary Hepatocytes, HepG2 Cells, and Corning HepatoCells
Mr Kevin Jones
Corning Life Sciences
28Cancer Therapeutic Screening in Tumor Spheroids Co-Cultured with Fibroblast and Immune Cells using Corning® Spheroid Microplates
Mr Kevin Jones
Corning Life Sciences
29Three Dimensional Hepatotoxicity Screening using Corning® HepatoCells, the Spheroid Microplate and the SCREEN-WELL® Hepatotoxicity library
Mr Kevin Jones
Corning Life Sciences
30High Content Screening of Corning® HepatoCells for Hepatotoxicity
Eve Rogers
University of Liverpool
31Exploring the Potential of the Physico-Mechanical Environment and Circadian Timing in Adult Stem Cell Differentiation
Dr Emma Shanks
CRUK Beatson Institute
32Iterative Data Multiplexing Identifies Therapeutic Candidates for Oral Squamous Cell Carcinoma
Dr Nuno Alves
Stevenage Bioscience Catalyst
33DiscoverAssist
Dr Nuno Alves
Stevenage Bioscience Catalyst
34DiscoverAssist
Dr Jey Jeyakumar
Plasticell Ltd
35A stem cell screening platform for discovery of chondrogenic small molecules and their drug targets
Dr Muhammad Awais
Liverpool University
36Development of Small Molecule Inhibitors of Cyclophilin D to Protect Mitochondrial Function ˗ Potential Use for the Treatment of Acute Pancreatitis
Mr Roy Edward
BioStatus Limited
37Monitoring Cell Death in Real-Time/Time-Lapse Studies
Dr Ruediger Bader
Hamamatsu Photonics UK Ltd
39Ca²⁺ mobilization assay to predict GPCR ligands safety profile in Cor.4U human cardiomyocytes
Mr Simon Lydford
Molecular Devices (UK) Ltd
40Assessing 2D & 3D cellular responses with the EarlyTox suite of cell viability and apoptosis reagents for plate reader and imaging systems
Mr Simon Lydford
Molecular Devices (UK) Ltd
41Morphometric Characterisation of Cancer Spheroid Cultures using 2D/3D Image Analysis & Confocal Imaging Techniques
Mr Andrew Green
DiscoverX
42Profiling Compounds in Human Primary Cell BioMAP® Systems for Drug Discovery and Development in Cancer Immunotherapy
Miss Shweta Sharma
Jamia Hamdard
43In-silico studies of novel, non-pteridine analogues as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors
Miss Apeksha Shrivastava
Jamia Hamdard
44Drug Designing of novel DPPIV enzyme Inhibitors using Computer Aided Techniques
Miss Martine Ballinger
MRC Technology
46Solving the screening bottleneck: 96-well format HT reformatting and expression of IgGs for screening.
Miss Arune Balaikaite
MRC Technology
47T-cell epitopes, virus-like particles and extracellular loop fusions for challenging antibody generation
Mr Sunil Kumar
SHOOLINI UNIVERSITY
48Immunostimulatory potential of a bioactive fraction (PBC) from Phyllostachys bambusoides in SRBC immunized balb/c mice
Dr Cristina-Ileana Ureche
SIRION BIOTECH
51Improving in vivo Application Through High Quality Viral Vector Technologies – Purity, Concentration & Vector Design as Key for Successful AAV Experiments
Miss Laurie Gordon
GSK
53A platform for measuring and understanding intracellular cell concentration
Mr Joseph Bradley
Scitegrity Limited
54Automated detection and control of controlled substances
Mr Adam Dickinson
Nexcelom BioScience
55A high-throughput image cytometry-based screening method for the detection of IL2-induced peripheral blood mononuclear cell-mediated cytotoxicity
Mr Adam Dickinson
Nexcelom BioScience
56A high-throughput 3D tumor spheroid screening method for drug discovery using imaging cytometry.
Mr Adam Dickinson
Nexcelom BioScience
57Comparison of label-free cell cytotoxicity image cytometric detection method to CellTiter-Glo®
Mr Adam Dickinson
Nexcelom BioScience
58Real-time Caspase 3/7 measurement of suspension and adherent cells using the Celigo® image cytometer
Mr Steve Brough
Key Organics
59Building a Diverse and Experimentally-Curated Fragment Library
Dr Andrea Lindemann
InSphero AG
60Characterization and application of 3D Multi-donor Human Liver Microtissues for predictive DILI testing
Dr Andrea Lindemann
InSphero AG
61A Novel Standardized In Vitro Islet Model System for Efficacy and Toxicity Testing in Pancreatic β-cells
Mr John Cuff
AstraZeneca
63Compounds in the right place at the right time!
Ms Sapna Desai
GSK
65Promiscuous Activation of the Mast-Cell Degranulation Receptor, Mrgprx2, Induces Adverse Histamine-Like Reactions in Clinically Relevant Species
Dr Bill Primrose
Ripptide Pharma
67A chemoenzymatic route to novel macrocycles
Dr J Malcolm Wilkinson
Kirkstall Ltd
68Organ on a chip : A Status Report on Worldwide Developments
Mr Bryon Ricketts
Avacta Life Sciences Ltd
69Generation and Formatting of Affimer® Biotherapeutics for the Inhibition of the PD-L1/PD-1 Pathway
Ms Chloe Koulouris
University of Sussex
72Characterisation of serine racemase as a novel approach to modulating NMDA receptor function
Mr james bennett
University of Oxford
73Chemical Tools For Exploring the Biology of the Epigenetic Readers BRD9 and BRD7.
Mr Thomas Christott
University of Oxford
75A Chemical Tool to investigate the biology of SMARCA and PB1(5)
Miss Silvia Cirillo
Sheffield University
76De novo designed short antimicrobial peptide as a potential siRNA delivery vector targeting cancer cells
Dr Steven van Helden
Pivot Park Screening Centre
77The European Lead Factory: an efficient open-innovation platform with unique screening capabilities
Mark Abbott
Peak Proteins Ltd.
78X-RAY CRYSTAL STRUCTURES OF HITS FROM A FRAGMENT BASED DISCOVERY PROGRAM ON EPIGENETICS TARGET BRD3
Dr Thierry Calmels
Bioprojet biotech
79A Duplexed assay for measurement of GPCR mediated calcium signaling and PathHunter -arrestin recruitment from single well using FDSS/-cell functional drug screening system
Dr Amaury Fernandez-Montalvan
Bayer
80Fast and Accurate Assessment of Binding Kinetics in HTS Format with kPCA and Genedata Screener
Mr Michael Rogers
University of Liverpool
81Small molecule inhibitors for Cyclophilin D
Dr Carol Trim
Canterbury Christ Church University
82The antimicrobial effects of animal venom
Miss Danielle McCullough
Canterbury Christ Church University
83Targeting breast cancer signalling pathways with animal venoms
Mrs Astrid Noerenberg
upcyte technologies GmbH
84Driving primary liver cells into proliferation - the upcyte® technology
Mr Jonas Stenberg
Ridgeview Instruments AB
85Real-time interactions on living immune cells
Miss Sarah Ash
AstraZeneca
86Development of a Co-culture Assay Amenable to HTS
Miss Victoria Miller
University of Sussex
87Identification of Potent and Selective Inhibitors to Investigate the Role of the Epithelial Sodium Channels in Neurodegeneration
Mr Muddasar Farooq
Sekisui XenoTech
88Evaluation of Ketoconazole and its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters
Miss Gina Washbourn
University of Liverpool
89The Synthesis and Biological Evaluation of Carbamoyl Triazoles as Potential Antituberculosis Protease Inhibitors
Mr Mohd Fuad Rahmat Sam
University of Liverpool
90Human Cell Perfusion Bioreactor Systems Utilising Biomaterials to create 3D Tissue Analogs of Stem Cell Niches for the Production of Red Blood Cells
Dr Friedrich Reinhard
GSK
91Two-dimensional thermal proteome profiling and chemoproteomics as orthogonal drug target profiling strategies
Dr malcolm haddrick
AstraZeneca
92Characterisation of stem cell derived cardiomyocyte spheroids using the CardioExcyte platform
Dr Qiuyu Wang
Manchester Metropolitan University
93Investigating the response of gastric cancer cells to arabinoxylan extracts in vitro
Miss Yasmine Alsaidi
Royal Holloway University of London
94Affinity peptidomics and the selection of protein markers for the early non-invasive detection of breast cancer
Dr Ingo Montenbruck
Proteros Biostructures
95Commonalities and differences in protein production, kinetic profiling and X-ray crystallography supporting drug discovery processes for biologicals versus small molecules
Dr Giorgia Salvagiotto
Cellular Dynamics International, A FujiFilm Company
96Human iPSC-derived Tissues as Novel Translational Models for Drug Discovery.
Dr patrick courtney
tec-connection
97Recent developments in the Smart Laboratory Enabled by Standards in Laboratory Automation
Ms Roslyn Lloyd
PerkinElmer
98Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections
Dr Matt Vassey
Aurelia Bioscience
99Novel 3-D micro-scaffold platform: A paradigm shift for cell-based screening
Miss Therese Dynes
AstraZeneca
100Accelerated plate generation for Screening assays and reduction in Design-Make-Test cycle timelines are facilitated by Automation and Process improvements in Compound Management
Dr John Malone
CN BioInnovations
101A microfluidic, 3D cell culture system for the mechanistic investigation of liver diseases and determination of compound efficacy.
Mr Peter Strapps
PerkinElmer
102Detection and Modulation of Extracellular Matrix Protein Deregulation in Human Prostate Carcinoma Cells Using AlphaLISA Technology.
Dr Louise Healy
Aurelia Bioscience
103Macrophage responses under hypoxic conditions – a drug target for the discovery of anti-cancer agents?
Dr Amy Prosser
Sygnature Discovery
1043D Cell Culture: A Valuable Tool For Drug Discovery
Mr Paul McGillan
University of Liverpool
105Design, Synthesis and Biological Evaluation of Novel 7-Amino Pyrazolopyrimidine Anti-Bacterial Compounds for the Treatment of Onchocerciasis and Lymphatic Filariasis.
Mr David Whalley
AstraZeneca Pharmaceuticals
106High-throughput determination of the binding kinetics of nuclear hormone receptor antagonists using TR-FRET
Dr Monica Mantri
University of Oxford
107Screening for small molecule inhibitors of a cytoplasmic Terminal Uridylyl Transferase implicated in the modulation of Let-7 tumor suppressor miRNA
Ms Aisha Alsfouk
Strathclyde University
108Development of selective IKKα inhibitors as a treatment for prostate cancer therapy
Mr Andrew Brierley
AstraZeneca
109Increasing Assay Precision by the Evaluation and Mitigation of Systematic Discrepancies in Compound Dispenses Following a Comparison of Technology Platforms
Dr Oliver Wehmeier
acCELLerate GmbH
110Testing Compounds for Drug Induced Phospholipidosis Using Assay Ready Cryopreserved HepG2 Cells
Ms Donna Potts
Agilent technologies
111Antibody Characterization Enabled by Automated Affinity Purification, Deglycosylation, IdeS Digestion, and Reduction
Miss Katie Duffell
University of Sussex
112Development of a Tool Inhibitor of GCN5 Towards the Treatment of ccRCC
Dr Julie Rainard
University of Dundee, ESC Newhouse
113Showing target engagement for HTS hits with Microscale Thermophoresis
Mr Kristian Bruce
GlaxoSmithKline
114Industrialising a Volatile Solvent Transfer (VST) method to incorporate un-weighable compounds into the GSK Screening collection
Mr Md. Saiful Islam
University of Oxford
116Controversial Story of a Fe(II) and 2OG dependent Oxygenase, JmjD6
Prof Jim Gallagher
University of Liverpool
117Developing therapies for the iconic disease alkaptonuria (AKU)
Prof Jim Gallagher
University of Liverpool
118In vitro models of bone formation and bone resorption
Dr Sharon Bahia
PHE Culture Collections
119The EBiSC Catalogue
Dr Sharon Bahia
PHE Culture Collections
120Utilisation of iPSCs in Drug Discovery and Development
Dr Fiona McCann
NDORMS, University of Oxford
121Localised inhibition of histone acetylation may offer a novel therapeutic strategy to down regulate the myofibroblast phenotype in Dupuytren’s disease
Dr Daniel Martinez Molina
Pelago Bioscience AB
122The Cellular Thermal Shift Assay (CETSA) - Label free, physiologically relevant target engagement measures in the intact cell
Mr Chris Evans
TTP Labtech
124Eliminating the false negatives in ATP-luminescence cell health assays by the use of a phenotypic based approach.
Mr Chris Evans
TTP Labtech
125A practical solution for phenotypic screening of a full compound library
Mr Gareth Jones
TTP Labtech
126Enriched datasets from in-house compound libraries using direct dilution methods in 1536 well plates
Mr Gareth Jones
TTP Labtech
127Low volume automated liquid handling for studying autophagic pathway, and cellular transduction in cancer cells
Miss Sarah Payne
TTP Labtech
128Multiplexed cell and bead based assays in a no wash format for biologics screening and characterisation
Miss Sarah Payne
TTP Labtech
129Beating Moore’s law but now what? Reduced sample prep cost for genetic analysis
Dr Karl Syson
John Innes Centre
130Remodelling α-glucan pathways in Mycobacterium tuberculosis and identifying new drug targets
Dr Adrian Kinkaid
MIP Diagnostics Limited
131Automatic Reactor for the Synthesis of MIP Nanoparticles
Dr Francesco Canfarotta
MIP Diagnostics Limited
132Imprinted Polymeric Nanoparticles for Diagnostic Applications
Dr Liz Quinn
Takara Bio USA, Inc.
133Footprint free genome editing via CRISPR/Cas9 and single cell cloning of human iPS cells
Dr Michael Elser
Takara Bio Europe
134Novel miniprep system for rapid purification of recombinant proteins and antibodies on high-capacity membranes
Mrs Keisha Hearn
Astex Pharmaceuticals
135Generation and characterisation of crizotinib-resistant NSCLC models
Dr Katie Chapman
Domainex
136An Important role for TBK1/IKKε in IP10 signalling: A potential intervention in COPD
Dr Jana Wolf
Domainex
137Fragment screening against the lysine methyltransferase G9a using Microscale Thermophoresis
Dr Cristina-Ileana Ureche
SIRION BIOTECH
138Optimization of in vitro gene therapies with LentiBOOSTTM, a novel clinical applicable adjuvant improving LV transduction efficiency in hematopoietic cells
Ms Irene Hallyburton
University of Dundee
139DDD107498: A Preclinical Candidate for Malaria
Mrs Amanda Jones
PerkinElmer
141Setting up a 3D High Content Imaging Assay to study Cholestasis using the Opera Phenix High Content Screening System
Dr Dale Athey
Orla Protein Technologies
142A protein-engineering approach to assay development for in-process analysis during antibody-drug conjugate manufacture: a proof of concept with trastuzumab
Dr Michael Thomas
Drug Discovery Unit
143DDD853651; A Preclinical Candidate for the Treatment of Visceral Leishmaniasis
Dr Priyanka Dutta-Passecker
Axol Bioscience Limited
144Serum-free Human iPSC-Derived Cardiomyocytes for in vitro testing
Dr Priyanka Dutta-Passecker
Axol Bioscience Limited
145Implementation of High Throughput Screening on iPS cells
Miss Jennifer Riley
University of Dundee
146Giving CYP the slip…Establishment of an in vitro CYP51 inhibition assay to prioritise new chemical entities for Chagas’ Disease.
Ms Laura Turunen
FIMM
147Acoustic dispensing in development of personalized medicine drug sensitivity and resistance testing (DSRT) platform at FIMM
Dr Richard Wall
University of Dundee
148Defining drug mechanism of action: leveraging phenotypic hits against kinetoplastids
Ms Rachel Harvey
AstraZeneca
149An Evaluation of iPSC-CM Cell Lines for Calcium Imaging Cardiotoxicity Screening
Dr Matthew Burnham
Astrazeneca
150Characterisation of stem cell derived cardiomyocyte spheroids using the CardioExcyte platform
Mr Neil Mallon
Caltag Medsystems Ltd
151Identification of Biomarkers for Ovarian Cancer using xxpress® qPCR
Dr Maja Petkovic
AMS Biotechnology (Europe) Limited
152Next generation high capacity DNA damage detection assay for chemotherapy and genotoxic compound screening
Dr Ann Macdonald
Thermo Fisher Scientific
154A robust platform for generation and high throughput functional analysis of human iPSC-derived cardiomyocytes
Dr Spencer Campbell
Bicycle Therapeutics
155Discovery and characterisation of a CAIX-targeted Bicycle-Drug Conjugate.
Mr Peter Craggs
GSK
156Autofluorescent and Active – the Use of Fluorescence Lifetime Technology to Eliminate False Fluorescent Hits
Mr Peter Craggs
GSK
157Long Fluorescence Lifetime or Label-free? An Evaluation of Fluorescence Lifetime Technology for High Throughput Screening
Dr Roland Leathers
Thermo Fisher Scientific
158Profiling Inhibitors with Full-Length LRRK2 in both Biochemical & Cellular Formats
Dr Valerie Legris
Electrospinning Company
159Growing hiPSC-derived cardiomyocytes on Mimetix scaffold improves their function
Mr Lauri Paasonen
UPM-Kymmene Corporation
1603D cell culture, assay automation and 3D printing demonstrated with a novel xeno-free hydrogel derived from wood
Dr Claire McWhirter
AstraZeneca
161Assay Design Impacts on Hits Found During Primary Screening
Mr Martin Brown
AstraZeneca
162Investigating Alternative Pathway Mechanisms of AhR Antagonism
Dr Roja Hadianamrei
University of Sheffield
163Short amphiphilic peptides as new tools for gene delivery
Mrs Margaret Huggett
DDU, University of Dundee
164Fragment Library Design, Synthesis & Expansion: Nurturing a Synthesis and Training Platform
Mrs Margaret Huggett
DDU, University of Dundee
165Small polar compound library for TB drug discovery
Mrs Margaret Huggett
DDU, University of Dundee
166Fragment Library Design, Synthesis & Expansion: Nurturing a Synthesis and Training Platform
Mrs Margaret Huggett
DDU, University of Dundee
167Small polar compound library for TB drug discovery
Mrs Margaret Huggett
DDU, University of Dundee
168Designing and building lead-like diversity libraries
Mrs Margaret Huggett
DDU, University of Dundee
169Identification and prioritisation of hits from whole cell phenotypic screening of Mycobacterium Tuberculosis in the context of treatment shortening
Dr Tony Hope
Drug Discovery Unit
170Innovative Targets: The DDU Approach
Mrs Samantha Hitchin
Cancer Research UK Manchester Institute
171CRUK:MI Advancing Drug Discovery Through Partnership
Miss Jennifer Bishop
Kirkstall
172Can Organ-on-a-Chip Replace Animal Testing of Drug and Chemical Safety?
Mrs Samantha Hitchin
Cancer Research UK Manchester Institute
173CRUK:MI Advancing Drug Discovery Through Partnership
Dr Hinnah Campwala
Essen BioScience
174Continuous live-cell proliferation, clustering and viability assays for T-cells, PBMCs, monocytes and B-cells
Mr Mike Kerins
Cambridge Bioscience
175Miniaturization Of Singulex® and Luminex® Multiplex Based Cytokine Assay With Wall Less 96 Well Plates
Mr Mike Kerins
Cambridge Bioscience
176Immunotherapeutic Target Identification & Drug Screening Using Patient Tumour & Blood Samples Cultured Under Conditions That Replicate The Metastatic Niche
Mrs Louise Affleck
Cisbio Bioassays
179Sensitive detection of GPCR-mediated ERK1/2 phosphorylations in various cellular models with the HTRF® advanced phospho-ERK1/2 kit
Mrs Louise Affleck
Cisbio Bioassays
180HTRF® phospho-protein platform facilitates the dissection of signaling pathways involved in insulin resistance and metabolic disorders
Mrs Louise Affleck
Cisbio Bioassays
181Implement HTRF® phospho-protein assays at every step of the drug discovery process: from in vitro to in vivo models
Mr Carl Jarman
Labcyte Inc.
182Identification of PI3K inhibitors with an Automated Echelon Fluorescence Polarization Assay Using the Labcyte Access Workstation with Integrated Labcyte Echo 525 and 555 Liquid Handlers and the EchoQualified Reservoir
Dr Daniella Steel
Horizon Discovery
183A generic strategy for CRISPR - Cas9-mediated gene tagging
Dr Hannes Hahne
OmicScouts GmbH
184Identifying drug targets and target engagement markers using proteome-wide CETSA and ITDR
Dr Gesa Rascher-Eggstein
Nanion Technologies GmbH
185Cardiac drug and safety screening platforms for the future: automated patch clamp, extracellular field potential and impedance approach
Mrs Emma Cains
Allergan Biologics
186Application of Automation/Technology for Improving Cell Line Development
Dr Peter Djali
IntelliCyt Corporation
187A High Throughput Screening Assay to Assess PD-LI/2 Antibody Checkpoint Inhibitors
Dr Cleoper Paule
Charles River Discovery
188HTMS Screen for Enzyme Inhibitors Utilising the Apricot ADDA for On-Line Sample Desalting
Prof Weili Li
University of Chester
189Investigating the response of gastric cancer cells to arabinoxylan extracts in vitro
Mr Tristan Pritchard-Meaker
Axiogenesis AG
190Human iPSC-derived cardiomyocytes for HTS to assess acute as well as chronic drug-induced cardiotoxicity